A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

@article{Stern2003ACH,
  title={A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*},
  author={Jerry O. Stern and Patrick A. Robinson and James E. Love and Stephan F. Lanes and Michael Imperiale and Douglas L. Mayers},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
  year={2003},
  volume={34},
  pages={S21-S33}
}
All classes of antiretroviral (ARV) therapy have been associated with asymptomatic elevations of alanine aminotransferase/aspartate aminotransferase (ALT/AST) levels, and much less frequently with serious, and at times life threatening, clinical liver hepatotoxicity. The relationship between the risk of developing serious clinical liver injury and the rate and severity of elevated asymptomatic ALT/AST levels is poorly understood. Boehringer Ingelheim has recently completed the Viramune® Hepatic… Expand
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
TLDR
The rate of severe hepatotoxicity, ALT and/or ASTlevels >5 times the upper limit of normal (ULN), during therapy with NNRTIs is relatively low but may be significantly higher in patients with concurrent chronic viral hepatitis (hepatitis B or C). Expand
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
TLDR
The use of nevirapine in female patients with a low BMI should be discouraged and the occurrence of early hepatotoxicity was 17% in the ne virapine group and 0% inThe efavirenz group and was balanced between the lamivudine and emtricitabine arms. Expand
Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens
TLDR
Gender and CD4+ T-cell count appeared to have a statistically significant impact on the risk of relevant transaminase level elevations in HCV-negative, but not inHCV-positive patients, probably due to a diluting effect of HCV. Expand
NEVIRAPINE HEPATOTOXICITY: IMPLICATIONS OF RISK FACTORS
TLDR
No correlation was found between pregnancy, CD4 cell count and gender with respect to nevirapine associated hepatotoxicity, but this leaves a space for further evaluation. Expand
Safety of fosamprenavir in a cohort of HIV-1-infected patients with co-morbidities.
TLDR
Fosamprenavir-based regimens caused a low number of serious metabolic adverse events during a 48 week follow-up period, with a low incidence of co-morbidities and satisfying results in terms of viro-immunological response including for patients with already existing co- Morbidities requiring other therapies. Expand
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
TLDR
HCV coinfection and ABCB1 rs1045642 SNP represent independent determinants of severe liver toxicity related to nevirapine, and could be included as toxicity assessment in HIV-1-positive subjects treated with ne virapine. Expand
Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon
TLDR
There was no significant rise in the mean level of transaminases and thus scheduling their routine monitoring at the end of the second week could be skipped, and the high prevalence of anaemia after a fortnight on treatment suggests a targeted instead of a routine monitoring; focusing on the high risk population with baseline anaemia and low body weight. Expand
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
UNLABELLED We assessed the safety and efficacy of different nevirapine-based regimens in patients starting this drug in a large cohort of Caucasian subjects during the 1999-2007 periods. METHODS AExpand
Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique
TLDR
Clinical signs and symptoms identified 50% of grade 3 HT and most cases of grade 4 HT, which suggests that in settings where alanine aminotransferase measurement is not feasible, nevirapine- and efavirenz-based ART may be given safely without laboratory monitoring. Expand
Anti-Retroviral Therapy Related Liver Injury (ARLI): A Series of 11 Cases.
TLDR
Anti-retroviral-related liver injury in HIV positive patients, their CD4+ cell counts, biochemical and viral markers and liver ultrasound indicates severe immunosuppression, and ARLI is recognised. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
TLDR
Hepatotoxicity but not clinical hepatitis was common in HIV-1-infected patients receiving nevirapine-containing regimens and the incidence steadily increased over time. Expand
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
TLDR
It is found that patients who use a protease inhibitor in a nevirapine-containing regimen and patients who have chronic hepatitis B (HBV) infection are at a higher risk for the development of increases in ASAT and/or ALAT to grade > or =2. Expand
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
TLDR
Patients with human immunodeficiency virus (HIV) type 1 infection who are starting to receive highly active antiretroviral therapy (HAART) and HBV-coinfected patients using 3TC should be considered, even if 3TC-resistant HIV strains develop. Expand
Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
TLDR
Liver damage is three times more common in patients receiving NVP than in those taking EFZ, and in both groups of patients, it is recognized late, after an average of 5.5 months on therapy. Expand
Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections
TLDR
Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors. Expand
Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.
TLDR
Hepatitis C coinfection and elevated ALT levels at HAART initiation are important predictors of progression to alanine aminotransferase levels > or =200 IU/L; stavudine-containing regimens were associated with a lower risk compared with zidovudineThe Lancet records suggest that highly active antiretroviral therapy is strongly effective in reducing morbidity and mortality in HIV-1-positive individuals. Expand
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
TLDR
Avoidance of alcohol abuse, especially in study subjects coinfected with HCV, will reduce the risk of hepatic injury after HAART, and older age should be considered. Expand
Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
TLDR
Hepatic cytolysis is more frequent among patients treated with HAART than with two NRTIs, and co-infections with hepatitis B virus or hepatitis C virus may modify the management of HIV-infected patients treated by HAART. Expand
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
TLDR
It is concluded that NNRTIs are relatively free from hepatotoxicity in this population of HIV-infected patients, despite the presence of coinfection with HBV or HCV. Expand
Mortality for liver disease in patients with HIV infection: a cohort study.
TLDR
Multivariate analysis showed that in-hospital liver-disease-related mortality was independently associated with hepatitis B surface antigen reactivity and history of alcohol abuse, which indicates that prevention and treatment of hepatitis B virus infection and alcohol intake are management priorities in HIV-seropositive patients. Expand
...
1
2
...